sodium phenylacetate + sodium benzoate

Sodium phenylacetate + sodium benzoate is an intravenous fixed-dose nitrogen-scavenging combination used as adjunctive emergency therapy for acute hyperammonemia and associated encephalopathy in pediatric and adult patients with urea cycle enzyme deficiencies. Phenylacetate conjugates glutamine to form phenylacetylglutamine, while benzoate conjugates glycine to form hippurate; both nitrogen-containing products are eliminated renally, providing alternative pathways for waste-nitrogen excretion when urea-cycle function is deficient. The reference product is marketed as **Ammonul** as a 10%/10% concentrated aqueous injection requiring dilution before intravenous infusion. Takeda developed an intravenous version under the code TAK-123 and completed a Japanese Phase 1 pharmacokinetic and safety study in healthy adults. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d564f2b1-9fc7-4201-8066-d745ac3a671f))

Brand names

Ammonul

Other names

NaPA + NaBZSPSBsodium benzoate + sodium phenylacetatesodium phenylacetate and sodium benzoatesodium phenylacetate/sodium benzoate